Li Ye

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

Lingxu Jiang, Yingwan Luo, Shuanghong Zhu et al. · Cancer Science · 2019 · 39 citations · Full text

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Xingnong Ye, Xinping Zhou, Juying Wei et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 31 citations

The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?

Lu Gao, Yang Liu, Li Ye et al. · Clinical Lymphoma Myeloma & Leukemia · 2022 · 24 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Peipei Lin, Yingwan Luo, Shuanghong Zhu et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 20 citations · Full text

Hematological Malignancy, Leukemic Transformation, Mixed-phenotype Acute Leukemia +9

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex

Lu Wang, Qi Zhang, Li Ye et al. · British Journal of Cancer · 2022 · 18 citations · Full text